In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens

Maged Al-Sherbiny, Ahmed Osman, Rashida Barakat, Hala El Morshedy, Robert Bergquist, Richard Olds

Research output: Contribution to journalArticleResearchpeer-review

74 Citations (Scopus)

Abstract

Few studies comparing schistosomiasis vaccine candidate antigens between laboratories have been carried out and published. Generally, only the investigators who discovered the molecules have evaluated them in either experimental animal models or in human correlate studies. In an attempt to identify responses against specific antigens and investigate their association with resistance versus susceptibility to re-infection, we studied the serological reactions and the cytokine responses stimulated by a panel of 10 candidate vaccine molecules in 225 long-term residents of an area endemic for Schistosoma mansoni in Egypt. The panel consisted of four recombinant antigens (Sm62-Irv5, Sm37-G3PDH, Sm28-GST and Sm14-FABP), one full-length native protein (Sm97-paramyosin), two synthetic peptides (MAP3 and MAP4) and three unpublished antigens (PR52-filamin, PL45-phosphoglycerate kinase, PN18-cyclophilin). Two different study designs, one based on retrospective and the other on prospective parasitological data were applied in the evaluation of the immune responses. Using historical data collected over the previous 5 years, correlations between frequency of re-infection and antigen-specific immune responses were investigated. In the prospective arm of the study, the subjects were followed over time after treatment with praziquantel with periodic immunological tests and stool examinations. Thus, highly specific humoral and cellular immune reactions in response to the 10 antigens described above could be correlated, both prospectively and retrospectively, with detailed epidemiological data covering a 66-month period. The immune response profiles produced were unique to each antigen but no clear "winner" or "winners" were identified. However, markers for both resistance and susceptibility to re-infection were identified for each molecule indicating which types of responses to aim for in vaccination and which ones to avoid. The insights gained from this approach should be useful for antigen selection and ultimately for vaccine formulation prior to Phase I/II trials in humans.

Original languageEnglish
Pages (from-to)117-130
Number of pages14
JournalActa Tropica
Volume88
Issue number2
DOIs
Publication statusPublished - 1 Oct 2003

Fingerprint

Schistosoma mansoni
humoral immunity
Vaccines
vaccines
antigens
Antigens
immune response
filamin
Infection
Filamins
infection
phosphoglycerate kinase
Phosphoglycerate Kinase
cyclophilins
Cyclophilins
praziquantel
recombinant antigens
Praziquantel
Tropomyosin
Immunologic Tests

Keywords

  • Cytokine response
  • Resistance to re-infection
  • Schistosomiasis
  • Vaccine

Cite this

Al-Sherbiny, Maged ; Osman, Ahmed ; Barakat, Rashida ; El Morshedy, Hala ; Bergquist, Robert ; Olds, Richard. / In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. In: Acta Tropica. 2003 ; Vol. 88, No. 2. pp. 117-130.
@article{ff6ab282a6f34f5da53f822079a168dd,
title = "In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens",
abstract = "Few studies comparing schistosomiasis vaccine candidate antigens between laboratories have been carried out and published. Generally, only the investigators who discovered the molecules have evaluated them in either experimental animal models or in human correlate studies. In an attempt to identify responses against specific antigens and investigate their association with resistance versus susceptibility to re-infection, we studied the serological reactions and the cytokine responses stimulated by a panel of 10 candidate vaccine molecules in 225 long-term residents of an area endemic for Schistosoma mansoni in Egypt. The panel consisted of four recombinant antigens (Sm62-Irv5, Sm37-G3PDH, Sm28-GST and Sm14-FABP), one full-length native protein (Sm97-paramyosin), two synthetic peptides (MAP3 and MAP4) and three unpublished antigens (PR52-filamin, PL45-phosphoglycerate kinase, PN18-cyclophilin). Two different study designs, one based on retrospective and the other on prospective parasitological data were applied in the evaluation of the immune responses. Using historical data collected over the previous 5 years, correlations between frequency of re-infection and antigen-specific immune responses were investigated. In the prospective arm of the study, the subjects were followed over time after treatment with praziquantel with periodic immunological tests and stool examinations. Thus, highly specific humoral and cellular immune reactions in response to the 10 antigens described above could be correlated, both prospectively and retrospectively, with detailed epidemiological data covering a 66-month period. The immune response profiles produced were unique to each antigen but no clear {"}winner{"} or {"}winners{"} were identified. However, markers for both resistance and susceptibility to re-infection were identified for each molecule indicating which types of responses to aim for in vaccination and which ones to avoid. The insights gained from this approach should be useful for antigen selection and ultimately for vaccine formulation prior to Phase I/II trials in humans.",
keywords = "Cytokine response, Resistance to re-infection, Schistosomiasis, Vaccine",
author = "Maged Al-Sherbiny and Ahmed Osman and Rashida Barakat and {El Morshedy}, Hala and Robert Bergquist and Richard Olds",
year = "2003",
month = "10",
day = "1",
doi = "10.1016/S0001-706X(03)00195-5",
language = "English",
volume = "88",
pages = "117--130",
journal = "Acta Tropica",
issn = "0001-706X",
publisher = "Elsevier",
number = "2",

}

In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens. / Al-Sherbiny, Maged; Osman, Ahmed; Barakat, Rashida; El Morshedy, Hala; Bergquist, Robert; Olds, Richard.

In: Acta Tropica, Vol. 88, No. 2, 01.10.2003, p. 117-130.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - In vitro cellular and humoral responses to Schistosoma mansoni vaccine candidate antigens

AU - Al-Sherbiny, Maged

AU - Osman, Ahmed

AU - Barakat, Rashida

AU - El Morshedy, Hala

AU - Bergquist, Robert

AU - Olds, Richard

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Few studies comparing schistosomiasis vaccine candidate antigens between laboratories have been carried out and published. Generally, only the investigators who discovered the molecules have evaluated them in either experimental animal models or in human correlate studies. In an attempt to identify responses against specific antigens and investigate their association with resistance versus susceptibility to re-infection, we studied the serological reactions and the cytokine responses stimulated by a panel of 10 candidate vaccine molecules in 225 long-term residents of an area endemic for Schistosoma mansoni in Egypt. The panel consisted of four recombinant antigens (Sm62-Irv5, Sm37-G3PDH, Sm28-GST and Sm14-FABP), one full-length native protein (Sm97-paramyosin), two synthetic peptides (MAP3 and MAP4) and three unpublished antigens (PR52-filamin, PL45-phosphoglycerate kinase, PN18-cyclophilin). Two different study designs, one based on retrospective and the other on prospective parasitological data were applied in the evaluation of the immune responses. Using historical data collected over the previous 5 years, correlations between frequency of re-infection and antigen-specific immune responses were investigated. In the prospective arm of the study, the subjects were followed over time after treatment with praziquantel with periodic immunological tests and stool examinations. Thus, highly specific humoral and cellular immune reactions in response to the 10 antigens described above could be correlated, both prospectively and retrospectively, with detailed epidemiological data covering a 66-month period. The immune response profiles produced were unique to each antigen but no clear "winner" or "winners" were identified. However, markers for both resistance and susceptibility to re-infection were identified for each molecule indicating which types of responses to aim for in vaccination and which ones to avoid. The insights gained from this approach should be useful for antigen selection and ultimately for vaccine formulation prior to Phase I/II trials in humans.

AB - Few studies comparing schistosomiasis vaccine candidate antigens between laboratories have been carried out and published. Generally, only the investigators who discovered the molecules have evaluated them in either experimental animal models or in human correlate studies. In an attempt to identify responses against specific antigens and investigate their association with resistance versus susceptibility to re-infection, we studied the serological reactions and the cytokine responses stimulated by a panel of 10 candidate vaccine molecules in 225 long-term residents of an area endemic for Schistosoma mansoni in Egypt. The panel consisted of four recombinant antigens (Sm62-Irv5, Sm37-G3PDH, Sm28-GST and Sm14-FABP), one full-length native protein (Sm97-paramyosin), two synthetic peptides (MAP3 and MAP4) and three unpublished antigens (PR52-filamin, PL45-phosphoglycerate kinase, PN18-cyclophilin). Two different study designs, one based on retrospective and the other on prospective parasitological data were applied in the evaluation of the immune responses. Using historical data collected over the previous 5 years, correlations between frequency of re-infection and antigen-specific immune responses were investigated. In the prospective arm of the study, the subjects were followed over time after treatment with praziquantel with periodic immunological tests and stool examinations. Thus, highly specific humoral and cellular immune reactions in response to the 10 antigens described above could be correlated, both prospectively and retrospectively, with detailed epidemiological data covering a 66-month period. The immune response profiles produced were unique to each antigen but no clear "winner" or "winners" were identified. However, markers for both resistance and susceptibility to re-infection were identified for each molecule indicating which types of responses to aim for in vaccination and which ones to avoid. The insights gained from this approach should be useful for antigen selection and ultimately for vaccine formulation prior to Phase I/II trials in humans.

KW - Cytokine response

KW - Resistance to re-infection

KW - Schistosomiasis

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0141679044&partnerID=8YFLogxK

U2 - 10.1016/S0001-706X(03)00195-5

DO - 10.1016/S0001-706X(03)00195-5

M3 - Article

VL - 88

SP - 117

EP - 130

JO - Acta Tropica

JF - Acta Tropica

SN - 0001-706X

IS - 2

ER -